{"filing":{"accession_number":"0001689548-26-000049","cik":"0001689548","ticker":"PRAX","company_name":"Praxis Precision Medicines, Inc.","form":"8-K","filing_date":"2026-05-07","report_date":null,"primary_document":"prax-20260507.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1689548/000168954826000049/prax-20260507.htm"},"events":[{"id":10270,"run_id":9006,"accession_number":"0001689548-26-000049","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"summary":"Praxis Precision Medicines disclosed quarterly financial results for Q1 2026 (quarter ended March 31, 2026) via a press release furnished as Exhibit 99.1 under Item 2.02.","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-05-07","form":"8-K","submitted_at":null,"items":[{"id":2,"accession_number":"0001689548-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses quarterly financial results for Q1 2026 (quarter ended March 31, 2026) via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:11:46.743930+00:00","company_name":"","ticker":null,"filing_date":""}]},{"id":10271,"run_id":9006,"accession_number":"0001689548-26-000049","anchor_item_number":"7.01","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"summary":"The company furnished a routine update to its corporate presentation for investor meetings under Regulation FD, explicitly disclaiming that the information is filed or incorporated by reference.","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-05-07","form":"8-K","submitted_at":null,"items":[{"id":3,"accession_number":"0001689548-26-000049","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes a routine update to the Company's corporate presentation for investor meetings, furnished under Regulation FD. The filing explicitly disclaims that the information is \"filed\" under Section 18 of the Exchange Act and is not incorporated by reference, indicating this is a standard administrative disclosure of investor relations materials rather than a material event requiring specific classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:11:46.743930+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":2,"accession_number":"0001689548-26-000049","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.98,"reasoning":"The filing discloses quarterly financial results for Q1 2026 (quarter ended March 31, 2026) via a press release furnished as Exhibit 99.1. This is a classic earnings release disclosure under Item 2.02, which would materially affect a reasonable investor's assessment of the company's financial performance and condition.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:11:46.743930+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-05-07"},{"id":3,"accession_number":"0001689548-26-000049","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":false,"confidence":0.85,"reasoning":"This disclosure describes a routine update to the Company's corporate presentation for investor meetings, furnished under Regulation FD. The filing explicitly disclaims that the information is \"filed\" under Section 18 of the Exchange Act and is not incorporated by reference, indicating this is a standard administrative disclosure of investor relations materials rather than a material event requiring specific classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:11:46.743930+00:00","company_name":"Praxis Precision Medicines, Inc.","ticker":"PRAX","filing_date":"2026-05-07"}]}